Parkinsonism-dementia (PD) of Guam is a neurodegenerative disease with parkinsonism and early-onset Alzheimer-like dementia associated with neurofibrillary tangles composed of hyperphosphorylated microtubule-associated protein, tau. β-N-methylamino-Lalanine (BMAA) has been suspected of being involved in the etiology of PD, but the mechanism by which BMAA leads to tau hyperphosphorylation is not known. We found a decrease in protein phosphatase 2A (PP2A) activity associated with an increase in inhibitory phosphorylation of its catalytic subunit PP2Ac at Tyr 307 and abnormal hyperphosphorylation of tau in brains of patients who had Guam PD. To test the possible involvement of BMAA in the etiopathogenesis of PD, we studied the effect of this environmental neurotoxin on PP2A activity and tau hyperphosphorylation in mouse primary neuronal cultures and metabolically active rat brain slices. BMAA treatment significantly decreased PP2A activity, with a concomitant increase in tau kinase activity resulting in elevated tau hyperphosphorylation at PP2A favorable sites. Moreover, we found an increase in the phosphorylation of PP2Ac at Tyr 307 in BMAA-treated rat brains. Pretreatment with metabotropic glutamate receptor 5 (mGluR5) and Src antagonists blocked the BMAAinduced inhibition of PP2A and the abnormal hyperphosphorylation of tau, indicating the involvement of an Src-dependent PP2A pathway. Coimmunoprecipitation experiments showed that BMAA treatment dissociated PP2Ac from mGluR5, making it available for phosphorylation at Tyr 307 . These findings suggest a scenario in which BMAA can lead to tau pathology by inhibiting PP2A through the activation of mGluR5, the consequent release of PP2Ac from the mGluR5-PP2A complex, and its phosphorylation at Tyr 307 by Src.
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Alzheimer's disease | amyotrophic lateral sclerosis | tauopathies | tau phosphorylation | cycad I ndigenous residents and immigrants of the Pacific Island of Guam suffer from a high incidence of a progressive and fatal neurodegenerative tauopathy called "parkinsonism-dementia" (PD). This is a long-latency disease with phenotypic characteristics of idiopathic parkinsonism with an early-onset dementia. The disorder is found together with a second high-incidence disease, amyotrophic lateral sclerosis (ALS). The incidence of both diseases has declined dramatically over the past half century, suggesting an environmental etiology (1) . The neuropathology of PD is hallmarked by neurofibrillary tangles (NFTs) (2) of paired helical filaments (PHFs) composed of abnormally hyperphosphorylated forms of the microtubule-associated protein tau. The NFTs found in PD brains are ultra-structurally and biochemically similar to those in Alzheimer's disease (AD) (3) . In contrast to AD pathology, however, studies using postmortem brains confirmed the absence of amyloid β plaques in most PD cases (2) . Many studies have demonstrated that abnormal hyperphosphorylation and aggregation of tau are crucial to neurodegeneration in AD and tauopathies (4) . Although the mechanism leading to the formation of NFTs is still obscure, it has been well recognized that an imbalanced regulation in protein kinases and protein phosphatases can directly cause AD-like tau hyperphosphorylation (4). Among the various kinases, glycogen synthase kinase-3β (GSK-3β), cyclin-dependent kinase 5, Ca 2+ / calmodulin-dependent protein kinase II (CaMKII), MAP kinase kinase (MEK 1/2), ERK 1/2, protein kinase A, casein kinase 1, and p70 S6 kinase have been most often implicated in tau phosphorylation (4) . Among the phosphatases, protein phosphatase 2A (PP2A) accounts for ∼70% of tau phosphatase activity in the human brain (5). PP2A is responsible for dephosphorylating most of the hyperphosphorylated sites of tau, and its activity is compromised in the AD brain (6) . Given the increasing evidence that PD histopathologically and genetically should be classified as a tauopathy (7, 8) , identifying the protein kinases/phosphatases and the associated signaling cascades that regulate tau phosphorylation is of crucial importance.
Several etiological factors, especially environmental factors, genetic susceptibility, and metabolic alterations, have been proposed to contribute to PD. The nonprotein amino acid β-Nmethylamino-L-alanine (BMAA) has been implicated as a potential environmental factor in PD, ALS, AD, and other neurodegenerative disorders (9) (10) (11) . Although the neurotoxic effects of BMAA are not conclusive, BMAA concentrations as low as 30 μM can cause selective death of motor neurons (12) , and a 10-μM concentration can potentiate neuronal injury induced by exposure to amyloid-β, 1-methyl-4-phenylpyridinium, or methylmercury in mixed cortical cultures (13) . The mechanism of BMAA toxicity is complex and several fold: (i) BMAA displays agonistic properties for NMDA (14) , AMPA/kainate (12) , and metabotropic glutamate receptor 5 (mGluR5) (14, 15) and for mGluR1 receptors (16) in a cell-specific manner, and (ii) it increases intracellular calcium levels (17) and oxidative stress (15) . BMAA was reported to induce learning and memory deficits accompanied by neuronal cell death in rats (18) , although the underlying molecular mechanism by which BMAA affects Significance Parkinsonism-dementia (PD) of Guam is a classical tauopathy in which abnormal hyperphosphorylation of tau leads to neurodegeneration and dementia. A key unresolved question is the mechanism of abnormal hyperphosphorylation of tau in this disease. This study reports the involvement of a signaling pathway in which the inhibition of protein phosphatase 2A (PP2A) through phosphorylation of its catalytic subunit PP2Ac at Tyr 307 induced by the activation of metabotropic glutamate receptor 5 (mGluR5) leads to hyperphosphorylation of tau. These findings suggest that the mGluR5-PP2A axis has a central role in neurofibrillary degeneration in Guam PD and thus may be a therapeutic target for the treatment of this disease and related tauopathies. tau phosphorylation and eventually toxicity has not been established.
In the present study, we report the involvement of PP2A signaling in PD and show that BMAA can produce similar changes by activating the mGluR5 receptor, leading to the dissociation of PP2A from the receptor, followed by its phosphorylation at Tyr 307 by Src, a nonreceptor tyrosine kinase. Phosphorylation of PP2A at Tyr 307 inhibits its activity and leads to hyperphosphorylation of tau. Together these data reveal an etiopathogenic mechanism of neurofibrillary pathology in PD, AD, and ALS involving mGluR5-dependent inactivation of PP2A. (19) and demethylation of its catalytic subunit, PP2Ac (20) . To examine whether PP2A inactivation is involved in abnormal hyperphosphorylation of tau in PD cases, we assayed the PP2A activity in autopsied brains from patients with Guam PD and age-matched controls from Guam by phosphatase ELISA (21) . We found a significant (P < 0.05) decrease in PP2A activity in PD compared with nonneurological controls from Guam (Fig. 1A) . PP2A is known to be down-regulated by phosphorylation at Tyr 307 (22) , demethylation at Leu 309 (23) , and endogenous inhibitors I PP2A 1 and I PP2A 2 (19, 24) . We looked for the possible involvement of all PP2A regulatory factors in PD. We observed a significant increase (P < 0.05) in PP2A phosphorylation at Tyr 307 in PD brains as detected by quantitative Western blot analysis ( Fig. 1 B and C). However, we did not detect any significant changes in the levels of demethylated PP2Ac or I ( Fig. 1 B and C). Western blots developed with phosphorylation-dependent/ site-specific tau antibodies revealed that tau phosphorylation increased at all phosphorylation sites examined in PD cases as compared with the controls (Fig. 1 D and E) . We also observed similar results in four cases of Guam PD and five age-matched nonneurological control cases from the United States mainland (Fig. S1 ). Interestingly, we found that the total tau level was markedly higher in PD cases than in the controls and displayed an upward gel mobility shift with higher molecular weight smears ( Fig. 1D and Fig. S1D ) that resemble those previously reported in AD (25) . These data suggested the involvement of Tyr 307 phosphorylation of PP2Ac in PD brain.
Results

PP2A
BMAA Inhibits PP2A, Increases Tau Hyperphosphorylation, and Causes Death of Hippocampal Neurons. Because BMAA has been widely suspected as a possible environmental toxin in the etiopathogenesis of PD (9-11), we investigated whether BMAA can inhibit PP2A activity, induce abnormal hyperphosphorylation of tau, and cause neuronal death. We determined the PP2A activity toward phosphorylated tau as a substrate after treatment with BMAA in mouse mixed primary neuronal cultures. We found that BMAA concentrations of 100 μM to 1 mM significantly decreased PP2A activity for 3-48 h without any detectable effect on its protein expression ( . Using a lactate dehydrogenase (LDH) release assay, we also observed that 1 mM BMAA caused cell death in mixed primary neuronal culture (Fig. 2G) , as is consistent with previous reports (12) (13) (14) . Collectively these results suggest that BMAA can cause cell death which is associated with the inhibition of PP2A and the increase in hyperphosphorylation of tau in primary neurons.
BMAA-Induced Hyperphosphorylation of Tau Is Associated with an Increase in PP2A Phosphorylation at Tyr 307 in Metabolically Active Brain Slices. To investigate (i) whether BMAA has an effect on tau hyperphosphorylation in brain similar to that seen in primary neuronal cultures and (ii) whether the PP2A signaling involved in this effect is similar to that found in PD brains, we treated metabolically active brain slices from adult Wistar rats with 1 mM BMAA for 2-3 h, determined the level of tau phosphorylation, and studied the involvement of PP2A and tau kinases regulated by it. We found that BMAA increased phosphorylation of tau at Ser 262/356 (3.4-fold), Ser 199 (2.6-fold), Thr 205 (1.8-fold), and Thr 212 (3.7-fold) ( Fig. S3 A and B) . As in primary hippocampal neurons, we did not find any significant change in the phosphorylation of tau at Ser 396 (Fig. S3B) . Next, we assayed PP2A activity and found a significant inhibition of PP2A activity in brain slices incubated with BMAA for 2 h in artificial cerebrospinal fluid (Fig. 3A) . To understand the mechanism underlying BMAA-induced down-regulation of PP2A, we measured phosphorylation of PP2A at Tyr 307 , demethylation at Leu 309 , and the levels of the PP2A inhibitors I PP2A 1 and I PP2A 2 . We found a dramatic (3.7-fold) increase in the phosphorylation of PP2Ac at Tyr 307 in BMAA-treated slices, but we detected no significant changes in the level of Leu 309 demethylated PP2A, I PP2A 1 , or I PP2A 2 ( Fig. 3 B and C) .
It is known that Src family kinases such as c-Src and Lck phosphorylate PP2Ac at Tyr 307 and inhibit its activity (22) . We therefore examined whether Src could play a role in BMAA-induced PP2A inactivation. We found that pretreatment with PP2, a broad-spectrum Src kinase inhibitor, blocked the BMAA-induced tau hyperphosphorylation in brain slices (Fig. 3 D and E) .
PP2A can regulate phosphorylation of tau both directly and through the activation of several tau protein kinases that are regulated by it (4). We therefore measured levels of total and activated/inactivated forms of several PP2A-regulated protein kinases. The levels of phosphorylated/activated CaMKII, ERK1/2, and MEK1/2 increased noticeably after treatment with BMAA (Fig. 3 F  and G) . However, we detected no significant changes in the levels of phosphorylated GSK-3β, JNK, or p70 S6 kinase in BMAAtreated brain slices. We further observed that the inhibition of PP2A activity by okadaic acid up-regulates ERK1/2 phosphorylation, similar to our findings following BMAA treatment (Fig. S4) . However, we cannot rule out the involvement of any nonspecific cytotoxic effect of BMAA in increasing the phosphorylation of ERK1/2. Collectively these results suggest that (i) inhibition of PP2A plays an important role in BMAA-induced tau hyperphosphorylation, (ii) the effect of BMAA is modulated both directly by PP2A and indirectly by the tau kinases that are regulated by PP2A, and (iii) the effect of BMAA on PP2A signaling in brain slices is similar to the effect we observed in PD brains.
BMAA Induces an Increase in Phosphorylation of PP2Ac at pTyr 307 and
Tau Hyperphosphorylation in Vivo in Rat Brain. Our observations in primary neuronal culture and brain slices prompted us to study the effect of BMAA on tau hyperphosphorylation in vivo in rat brain. Because of poor blood-brain barrier permeability of BMAA in the adult as compared with the neonatal brain (26), we selected newborn rats for these studies. We administered BMAA intracerebroventricularly (i.c.v.) in neonatal rats and then at various time points analyzed their brains for changes in PP2A
and hyperphosphorylation of tau. We found that after BMAA treatment the level of phosphorylation of PP2Ac at Tyr 307 in rat brains increased markedly for 24-48 h and then decreased to a normal level by 72-96 h (Fig. 4 A and B) . Correspondingly, PP2A activity decreased, and this change was most significant at 48 h after BMAA treatment (Fig. 4C) (Fig. 4D) ; in vehicle-treated rats the hyperphosphorylation of tau at all the sites studied also reached the highest levels by 72-96 h. Together these findings revealed that the effect of BMAA on PP2A signaling in vivo in rat brain was similar to the changes in PP2A we observed in PD brains and that hyperphosphorylation of tau at Ser PP2A Reverses BMAA-Induced Tau Hyperphosphorylation. To confirm the role of PP2A in BMAA-induced tau hyperphosphorylation, we treated the metabolically active rat brain slices with D-Erythro-S (DES), a PP2A activator (27) , or expressed wild-type DsRedtagged PP2Ac in primary neurons before BMAA treatment. We found that either activation of PP2A (Fig. 5 A and B) or overexpression of PP2Ac (Fig. 5 C and D and Fig. S5 ) blocked the BMAA-induced tau hyperphosphorylation.
To evaluate whether BMAA has any direct effect on PP2A, we carried out an in vitro PP2A activity assay using bovine purified PP2A holoenzyme in the presence or absence of BMAA (Fig. 5E) . We found no effect of BMAA on PP2A activity. Collectively these findings suggest that BMAA does not promote PP2A inactivation directly but most probably affects its signaling. (Scale bar, 100 μm.) (Magnification: 40×.) (G) LDH release was measured 24 h after treatment with BMAA (1 mM) in cultured neurons; 2 mM glutamate was used as a positive control. Data are expressed as mean ± SEM for three separate experiments. *P < 0.05; **P < 0.01. Fig. 3 . BMAA induces an increase in pTyr 307 PP2Ac, inhibits the phosphatase activity, and activates several tau protein kinases in rat brain slices. Rat hippocampal brain slices were treated with BMAA (1 mM) for 2 h, and the tissue homogenate was used for Western blots and to measure PP2A activity. To identify the up-stream molecular mechanism involved in BMAA-induced PP2A (Tyr 307 ) phosphorylation, we incubated rat brain slices with and without 2-methyl-6-(phenylethynyl) pyridine (MPEP, an antagonist of mGluR5), MK-801 (an antagonist of NMDA), or 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX, an antagonist of AMPA) for 30 min before the addition of BMAA. We found that preincubation of the brain slices with 50 μM MPEP significantly blocked tau hyperphosphorylation at the 12E8 site induced by BMAA, but no significant change was observed when the slices were treated with either MK-801 (10 μM) or CNQX (20 μM) alone (Fig. 6 A and B) . The BMAAinduced decrease in PP2A activity was blocked completely by pretreatment with MPEP but not with MK-801 or CNQX (Fig.  6C) . Interestingly, cotreatment with MPEP and MK-801 entirely prevented the BMAA-induced tau hyperphosphorylation and PP2A inhibition. These data suggest that the activation of the mGluR5 receptor might be primarily involved in the inactivation of PP2A and the resultant hyperphosphorylation of tau in BMAA-treated brain slices. PP2A is known to be associated with mGluR5, and activation of mGluR5 leads to the dissociation of PP2A from this receptor and consequently to PP2A inactivation (28) . To confirm whether mGluR5 activation is the underlying cause of PP2A inactivation through dissociation, we carried out coimmunoprecipitation experiments and analyzed the amount of PP2Ac associated with mGluR5 in primary neurons in the presence or absence of 1 mM BMAA. We found that the treatment of the primary neuronal cultures with BMAA led to the dissociation of PP2Ac from mGluR5, and cotreatment with MPEP completely blocked the dissociation of PP2A from the receptor (Fig. 6 D and E) . These data suggest that BMAAinduced mGluR5 activation probably leads to the dissociation and consequently to the inactivation of PP2A by its phosphorylation at Tyr 307 .
Discussion
Neurofibrillary pathology made up of abnormally hyperphosphorylated tau is a hallmark of several neurodegenerative diseases which, in addition to PD, include AD, frontotemporal dementia-tau, Pick disease, cortico-basal degeneration, progressive supranuclear palsy, and adults with Down syndrome, suggesting that several different etiopathogenic mechanisms probably lead to this lesion. Thus, elucidation of these various mechanisms is critical for the development of rational therapeutic drugs for these diseases and is a major goal in the field. Off and on, over the last five decades, BMAA has been considered a candidate neurotoxin in Guam ALS and PD, but experimental evidence to support its role has been lacking. The present study identifies the association of tau pathology with a decrease in PP2A activity and increased phosphorylation of PP2Ac at Tyr 307 as a cause of this deficit in the phosphatase activity in PD. Furthermore, we show that all the changes in PD brains that we described above can be replicated by treatment with BMAA in rat brain. We found that treatment with BMAA (i) can produce an increase in phosphoTyr 307 -PP2Ac, (ii) can inhibit PP2A activity, and (iii) can produce abnormal hyperphosphorylation of tau in hippocampal primary neurons, in metabolically active brain slices, and in vivo in rats. Finally, using primary neurons and brain slices, we show that BMAA produces the increase in phospho-Tyr 307 -PP2Ac and consequent hyperphosphorylation of tau by activating mGluR5, leading to the dissociation of PP2Ac from the receptor and then its phosphorylation at Tyr 307 by Src. Although we did not measure Src activity in our studies, the report that Src activity is upregulated mainly through Tyr 416 phosphorylation (29) certainly rules out the direct possible involvement of BMAA, because it is not a kinase. This molecular mechanism (Fig. 7) is different from that involving cerebral ischemia and hypoxia, which inhibit PP2A by the activation of asparaginyl endopeptidase and the consequent cleavage and translocation of I 2 PP2A in AD and ALS (6, 19, 21, 30) .
BMAA exposure is not localized to Guam but rather is ubiquitous throughout the world (31) . BMAA can enter the food chain from cyanobacteria, can be incorporated into plant and animal proteins, and can be bio-concentrated in the ecosystem In vitro PP2A activity was measured using purified PP2A holoenzyme in the presence or absence of BMAA. Data are expressed as mean ± SEM for three separate experiments. *P < 0.05; **P < 0.01. (32, 33) . The bound form of BMAA may function as an endogenous neurotoxic reservoir, releasing free BMAA and causing neurodegeneration (34) . BMAA promotes neuronal death both in vitro and in vivo (15, 18, 35) . In the present study, we found that 1 mM BMAA caused cell death in mixed primary neuronal cultures. We used 1 mM BMAA for most of the experiments, considering that the reported average brain concentrations of the compound in Guam PD and North American AD cases were 627 μg/g, 5 mM and 95 μg/g, 0.8 mM, respectively (9, 36) . Therefore, the 1-mM BMAA concentration used in our experimental paradigms for modeling PD-related pathology is highly relevant. In the AD brain phospho-Tyr 307 -PP2Ac is increased (37) , and phosphatase activity is decreased (6) . Thus, taken together, the results in the present study support the idea that tau phosphorylation might result from an environmental as well as from an endogenous toxin such as BMAA and that this mechanism could be common to AD, PD, and ALS.
In the present study, we found that the inhibition of PP2A activity could be accounted for by the phosphorylation of PP2Ac at Tyr 307 . We obtained similar results in the rat brain slices and in vivo in rat brain by treatment with BMAA. Preincubation of brain slices with PP2, an inhibitor of Src responsible for PP2A (Tyr 307 ) phosphorylation, significantly attenuated BMAA-induced tau phosphorylation, suggesting that BMAA may inhibit PP2A through Tyr 307 phosphorylation. The critical role of PP2A in BMAA-induced tau hyperphosphorylation was confirmed further by both pharmacological and genetic approaches; the activation of PP2A by DES in brain slices and the overexpression of PP2Ac in primary neuronal cultures entirely prevented the hyperphosphorylation of tau when treated with BMAA. The increase we observed in the activation of CaMKII, ERK1/2, and MEK1/2 by BMAA in rat brain slices probably is secondary to the inhibition of PP2A, which is known to regulate these kinases (4 . In contrast, we observed that pSer 396 expression was unchanged in BMAAtreated mouse hippocampal primary neuronal cultures, hippocampal brain slices, and even in in vivo rat brain. The apparent discrepancies may be caused by the genomic and cellular complexity of human vs. mouse/rat tissues. Another possible explanation could be that Ser 396 is the least favorable site for dephosphorylation by PP2A (5, 43) in response to BMAA treatment. Based on the data in the present study, it is reasonable to delineate an association between disease progression and abnormal hyperphosphorylation of tau at specific sites in PD, similar to those reported previously in AD (42, 44) .
The present study suggests the direct involvement of a PP2A-dependent disease mechanism. PP2A has been shown to form a complex with NMDA (45) and mGluR5 (28) receptors, and dissociation of PP2A from these receptors reduces PP2A activity. Moreover, BMAA has been reported to affect all the main glutamate receptors, i.e., NMDA, AMPA/kainate, and metabotropic receptors (35) . This evidence suggests that the effect of BMAA on either NMDA or mGluR5 can facilitate PP2A inactivation through dissociation from the receptor. In the present study, however, we found that activation of mGluR5, but not of the NMDA receptor, was responsible for BMAA-induced tau hyperphosphorylation in brain slices. The exact reason underlying the selective action of BMAA on mGluR5 is not known. Possible explanations include the predominant expression of mGluR5 in hippocampal neurons and the particular localization of mGluRs on the dendritic membrane (46) making the receptor selectively accessible to BMAA. In the present study, coimmunoprecipitation experiments further confirmed that the activation of mGluR5 dissociates PP2A from the mGluR5 receptor. Taken together, the results of the present study suggest that activation of mGluR5 facilitates a series of biochemical events, including dissociation of PP2A from mGluR5, Tyr 307 phosphorylation of PP2Ac, reduction of PP2A activity, and tau hyperphosphorylation.
In summary, based on the findings in the present study, we propose the involvement of a mechanistic pathway underlying the neurofibrillary degeneration in PD, so that an environmental toxin, such as BMAA, down-regulates PP2A activity and induces tau hyperphosphorylation by activating mGluR5; the activation of mGluR5 results in the dissociation of PP2Ac from the receptor, followed by its phosphorylation at Tyr 307 by Src.
Materials and Methods
Two sets of frozen autopsied tissue samples of frontal cortices from histopathologically confirmed Guam PD cases and age-matched controls were used. The first set consists of eight Guam PD cases and seven nonneurological controls from Guam ( Fig. 1 and Table S1 ); the second set comprises four Guam PD cases and five nonneurological controls from the United States mainland ( Fig. S1 and Table S2 ). For detailed information on these cases, mouse embryonic day 18 hippocampal primary neuronal cultures and transfections, preparation of rat brain slices, BMAA treatment, i.c.v. infusion of rat pups with BMAA, coimmunoprecipitation, PP2A activity assays, SDS/ PAGE, Western blots, densitometry, immunofluorescent staining, and statistical analyses, see SI Materials and Methods.
